Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1996 2
1997 1
1998 3
1999 2
2000 1
2001 2
2003 1
2008 1
2009 1
2010 1
2011 1
2013 2
2014 3
2017 1
2018 2
2019 3
2020 2
2021 2
2022 1
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Dietz J, Graf C, Berg CP, Port K, Deterding K, Buggisch P, Peiffer KH, Vermehren J, Dultz G, Geier A, Reiter FP, Bruns T, Schattenberg JM, Durmashkina E, Gustot T, Moreno C, Trauth J, Discher T, Fischer J, Berg T, Kremer AE, Müllhaupt B, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39006503 Free PMC article.
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Berg T, et al. Among authors: sick c. Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15. Aliment Pharmacol Ther. 2019. PMID: 30874328
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Clin Gastroenterol Hepatol. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6. Clin Gastroenterol Hepatol. 2021. PMID: 31706062 Free article.
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
Li M, Mindt S, Lück A, Hutzschenreuter U, Kollendt M, Lathan B, Zöller T, Frank-Gleich S, Lorentz C, Lamberti C, Sick C, Zingerle M, Tesch H, Stein W, Hebart H, Stosiek C, Sandner R, Fries S, Burkholder I, Hofheinz RD. Li M, et al. Among authors: sick c. ESMO Open. 2023 Apr;8(2):101201. doi: 10.1016/j.esmoop.2023.101201. Epub 2023 Mar 23. ESMO Open. 2023. PMID: 36965262 Free PMC article.
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). de Salazar A, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. J Antimicrob Chemother. 2020. PMID: 32772078
31 results